New development in CAR-T cell therapy.
New development in CAR-T cell therapy.
复制标题
CAR-T细胞疗法新进展
DOI：
10.1186/s13045-017-0423-1
复制
发表时间：
2017-02-21
影响因子：
28.5
通讯作者：
Han W
中科院分区：
文献类型：
--
作者：
Wang Z;Wu Z;Liu Y;Han W
嵌合抗原受体(CAR)基因工程的T细胞(CAR-T细胞)在治疗B细胞恶性肿瘤方面取得了前所未有的疗效，尤其是在抗CD19的CAR-T细胞治疗B细胞急性淋巴细胞白血病(B-ALL)时，完全缓解率高达90%。然而，肿瘤抗原逃逸已经成为这种有希望的B细胞恶性肿瘤免疫疗法长期控制疾病的主要挑战。此外，这一成功在向实体肿瘤的转化方面遇到了重大障碍，而正常组织靶上/肿瘤外识别的安全性是主要原因之一。在这篇简短的综述中，我们描述了抗原丢失复发的一些机制和解决这个问题的新策略。此外，我们讨论了一些正在考虑的新的汽车设计，以提高CAR-T细胞治疗实体瘤的安全性。
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being considered to enhance the safety of CAR-T cell therapy in solid tumors.